RFA-DA-26-034-Full-Announcement.html

This document is a Request for Application (RFA) for the Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed).

The RFA is issued by the Department of Health and Human Services' National Institutes of Health and will support research to understand and mitigate the deleterious effects of acute exposure to UPS opioids such as fentanyl and their combinations. Eligible applicants include a wide range of organizations, including public or Indian housing authorities, higher education institutions, state/local governments, and nonprofits. The funding opportunity falls under the Drug Use and Addiction Research Programs (CFDA 93.279) and the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant programs. No application deadline or award dates are specified.